Antiinflamatorios no Esteroideos/uso terapéutico; Trastorno Depresivo Mayor/tratamiento farmacológico; Pirazoles/uso terapéutico; Sulfonamidas/uso terapéutico; Celecoxib; Bases de Datos Bibliográficas/estadística & datos numéricos; Humanos

BDNF; CENTRAL; CNS; Cochrane Central Register of Controlled Trials; DSM-IV; DSM-IV, text revision; DSM-IV-TR; Depression; Diagnostic and Statistical Manual for Mental Disorders, fourth edition; GENDEP; Genome-Based Therapeutic Drugs for Depression; HRSD; Hamilton Rating Scale for Depression; IDO; IFN-α; IL-1ß; IL-6; Inflammation; LPS; MADRS; MDD; Major Depressive Disorder; Meta-analysis; Montgomery­Asberg Depression Rating Scale; NSAID; PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT; Randomized controlled trials; SSRI; STAR*D; Sequenced Treatment Alternatives to Relieve Depression; TNF-α; WHO; WMD; World Health Organization; brain-derived neurotrophic factors; central nervous system; high sensitivity C-reactive protein; hs-CRP; indoleamine 2,3-dioxygenase; interferon-alpha; interleukin-1beta; interleukin-6; lipopolysaccharide; non-steroidal anti-inflammatory drug; randomized controlled trial; selective serotonin reuptake inhibitor; tumor necrosis factor-alpha; weighted mean difference